Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial
- Resource Type
- Article
- Source
- In
The Lancet Respiratory Medicine June 2017 5(6):484-491 - Subject
Primary Research Articles - Language
- ISSN
- 2213-2600